It’s why this Budget includes a further $1.3 billion to continue our public health response to COVID-19.
This investment backs the ongoing efforts of our contact tracers and public health team, while also supporting Australia's vaccine roll-out here in Victoria.
Establishing local manufacturing capability
A further $50 million will support establishing Victoria’s capability to manufacture mRNA vaccines, providing certainty of supply for new vaccines and lifesaving treatments in Australia.
Victoria is ideally placed to lead in mRNA production, and the Victorian Government will work closely with the Commonwealth and world-leading experts from Monash University, the University of Melbourne, the Doherty Institute and other leading research institutes, as well as domestic and international medical technology manufacturers, to develop the first mRNA manufacturing capability in the southern hemisphere.
Increasingly, mRNA and other forms of RNA nanomedicines can be used in the treatment of cancer, rare diseases, and protein-replacement therapy.
These vaccines also offer a promising alternative to traditional vaccines because of their efficacy, capacity for rapid development, low-cost manufacture, and safe administration.
Securing the Victorian production of mRNA will create new local jobs, and ensure our state remains a world leader in infectious disease research and treatment.
Reviewed 20 May 2021